Medexus Pharmaceuticals Inc (MDP) Stock Forecast & Price Target

Compare

65 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MDP Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Medexus

Pharmaceuticals Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MDP Stock 12 Month Forecast

Average Price Target

C$6.00

▲(129.01% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Medexus Pharmaceuticals Inc in the last 3 months. The average price target is C$6.00 with a high forecast of C$6.00 and a low forecast of C$6.00. The average price target represents a 129.01% change from the last price of C$2.62.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"C$1","4":"C$4","7":"C$7","2.5":"C$2.5","5.5":"C$5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,3.046153846153846,3.292307692307692,3.5384615384615383,3.7846153846153845,4.030769230769231,4.276923076923077,4.523076923076923,4.769230769230769,5.015384615384615,5.2615384615384615,5.507692307692308,5.753846153846154,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,3.046153846153846,3.292307692307692,3.5384615384615383,3.7846153846153845,4.030769230769231,4.276923076923077,4.523076923076923,4.769230769230769,5.015384615384615,5.2615384615384615,5.507692307692308,5.753846153846154,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,3.046153846153846,3.292307692307692,3.5384615384615383,3.7846153846153845,4.030769230769231,4.276923076923077,4.523076923076923,4.769230769230769,5.015384615384615,5.2615384615384615,5.507692307692308,5.753846153846154,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetC$6.00

Average Price TargetC$6.00

Lowest Price TargetC$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Martin PhD

Bloom Burton

C$6

Buy

129.01%

Upside

Reiterated

11/14/25

Medexus Pharmaceuticals Inc.: Stable Growth and Promising Outlook Justify Buy Rating

Michael W. Freeman

Raymond James

C$8

Buy

205.34%

Upside

Reiterated

08/14/25

Raymond James Sticks to Its Buy Rating for Medexus Pharmaceuticals Inc (MDP)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$6

Buy

129.01%

Upside

Reiterated

06/26/25

Canaccord Genuity Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$5.75→C$6

Buy

129.01%

Upside

Reiterated

02/06/25

Justin Keywood

Stifel Nicolaus

C$6→C$3.45

Hold

31.68%

Upside

Downgraded

02/06/25

Medexus Pharmaceuticals Inc.: Balancing Growth Potential and Risks with a Hold Rating

Stefan Quenneville

Ventum Financial

C$5→C$6.25

Buy

138.55%

Upside

Reiterated

01/30/25

Ventum Financial Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$3.5→C$6.25

Buy

138.55%

Upside

Reiterated

01/22/25

Unknown Analyst

Leede Financial

Not Ranked

Leede Financial

―

Buy

―

Upgraded

01/22/25

Unknown Analyst

Alliance Global Partners

Not Ranked

Alliance Global Partners

C$4

Buy

52.67%

Upside

Initiated

12/23/24

Alliance Global Partners starts Medexus Pharmaceuticals Inc. (MEDXF) at BuyAlliance Global Partners initiates coverage on Medexus Pharmaceuticals Inc. (OTC: MEDXF) with a Buy rating and a price target of $4.00.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Martin PhD

Bloom Burton

C$6

Buy

129.01%

Upside

Reiterated

11/14/25

Medexus Pharmaceuticals Inc.: Stable Growth and Promising Outlook Justify Buy Rating

Michael W. Freeman

Raymond James

C$8

Buy

205.34%

Upside

Reiterated

08/14/25

Raymond James Sticks to Its Buy Rating for Medexus Pharmaceuticals Inc (MDP)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$6

Buy

129.01%

Upside

Reiterated

06/26/25

Canaccord Genuity Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$5.75→C$6

Buy

129.01%

Upside

Reiterated

02/06/25

Justin Keywood

Stifel Nicolaus

C$6→C$3.45

Hold

31.68%

Upside

Downgraded

02/06/25

Medexus Pharmaceuticals Inc.: Balancing Growth Potential and Risks with a Hold Rating

Stefan Quenneville

Ventum Financial

C$5→C$6.25

Buy

138.55%

Upside

Reiterated

01/30/25

Ventum Financial Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$3.5→C$6.25

Buy

138.55%

Upside

Reiterated

01/22/25

Unknown Analyst

Leede Financial

Not Ranked

Leede Financial

―

Buy

―

Upgraded

01/22/25

Unknown Analyst

Alliance Global Partners

Not Ranked

Alliance Global Partners

C$4

Buy

52.67%

Upside

Initiated

12/23/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medexus Pharmaceuticals Inc

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

+6.10%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +6.10% per trade.

3 Months

xxx

Success Rate

6/11 ratings generated profit

Average Return

+10.21%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +10.21% per trade.

1 Year

Stefan QuennevilleVentum Financial

Success Rate

7/11 ratings generated profit

Average Return

+14.71%

reiterated a buy rating 11 months ago

Copying Stefan Quenneville's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +14.71% per trade.

2 Years

xxx

Success Rate

9/11 ratings generated profit

Average Return

+36.93%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +36.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDP Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MDP has received 4 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. MDP average Analyst price target in the past 3 months is 6.00.

Each month's total comprises the sum of three months' worth of ratings.

MDP Financial Forecast

MDP Earnings Forecast

Next quarter’s earnings estimate for MDP is -C$0.03 with a range of -C$0.06 to -C$0.01. The previous quarter’s EPS was -C$0.01. MDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MDP has Performed in-line its overall industry.

MDP Sales Forecast

Next quarter’s sales forecast for MDP is C$36.25M with a range of C$35.13M to C$38.78M. The previous quarter’s sales results were C$34.08M. MDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MDP has Performed in-line its overall industry.

MDP Stock Forecast FAQ

What is TSE:MDP’s average 12-month price target, according to analysts?

Based on analyst ratings, Medexus Pharmaceuticals Inc’s 12-month average price target is 6.00.

What is TSE:MDP’s upside potential, based on the analysts’ average price target?

Medexus Pharmaceuticals Inc has 129.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TSE:MDP a Buy, Sell or Hold?

Medexus Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Medexus Pharmaceuticals Inc’s price target?

The average price target for Medexus Pharmaceuticals Inc is 6.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is C$6.00 ,the lowest forecast is C$6.00. The average price target represents 129.01% Increase from the current price of C$2.62.

What do analysts say about Medexus Pharmaceuticals Inc?

Medexus Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of TSE:MDP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Medexus Pharmaceuticals Inc (MDP) Stock Forecast & Price Target

MDP Analyst Ratings

MDP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medexus Pharmaceuticals Inc

MDP Analyst Recommendation Trends

MDP Financial Forecast

MDP Earnings Forecast

MDP Sales Forecast

MDP Stock Forecast FAQ

Detailed List of Analyst Forecasts